Table 2.
Drugsb | F (%) |
AUC (μg.min/m L) |
t½β (h) | CL (mL/min/ kg) |
Vd (L/kg) |
Tmax (h) |
Cmax (μg/mL) |
|
---|---|---|---|---|---|---|---|---|
2 | iv | 2,650 | 22 | 18.9 | 0.37 | |||
po | 100 | 2,620 | 40 | 2 | 2.5 | |||
3 | iv | 3,520 | 9.6 | 5.68 | 4.73 | |||
po | 97 | 4,060 | 18.6 | 6 | 2.34 | |||
Linezo lidc |
iv | 606 | 0.55 | 16.3 | 0.63 | |||
po | 72.5 | 440 | 0.65 | 0.33 | 6.5 |
F - oral bioavailablity; AUC - area under the curve; t½β- terminal half-life; t½elim - elimination half-life; CL – clearance; Vd – Volume of distribution; Tmax – Time at which peak serum concentration was achieved; Cmax – peak serum concentration.
Compound 2 was administered iv and po at 50 mg/kg, 3 at 20 mg/kg and linezolid at 10 mg/kg.
Data reproduced from Slatter et al. 2002 [29] for comparison.